FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 245 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR The long road to targeting the holy grail of the immune... November 9, 2020 DIY Mosquito Traps & Deterrents (That Really Work) June 23, 2021 Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities October 22, 2021 ESMO Targeted Anticancer Therapies Congress 2021, 1-2 March February 23, 2021 Load more HOT NEWS New Safety Signal for Use of Ibrutinib in Combination with Rituximab... Here’s Why We’re Building Pet-Friendly Domestic Violence Shelters–And How You Can... PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients... EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of...
